Literature DB >> 15340736

[AGE-RAGE: a hypothesis or a mechanism?].

Berend Isermann1, Angelika Bierhaus, Per M Humpert, Gottfried Rudofsky, Triantafyllos Chavakis, Robert Ritzel, Thoralf Wendt, Michael Morcos, Christian Kasperk, Andreas Hamann, Peter P Nawroth.   

Abstract

Acausal relation between hyperglycemia and accelerated atherosclerosis has been recently suggested. The AGE-RAGE interaction is a potential mechanism underlying the accelerated atherosclerosis. Hyperglycemia causes via nonenzymatic glycation the formation of AGEs (advanced glycation endproducts). AGEs as well as other ligands like S100/Calgranulin and Amphoterin mediate receptor-independent and -dependent (via the interaction with RAGE) effects. The ligand-RAGE-interaction results in an activation of NF-kappaB, increased expression of cytokines, chemokines, and adhesion molecules and induces oxidative stress. A relevant role of the ligand-RAGE-interaction has been demonstrated in in vivo studies, both for the accelerated atherosclerosis and increased neointima formation in diabetes mellitus. Recent data analysing atherosclerotic lesions of diabetic patients provide further evidence for the pathogenetic role of the RAGE-ligand-interaction. In addition, new experimental data established that AGEs interact with other receptors than RAGE, while RAGE interacts with a diverse group of ligands. Thus, further studies are needed for the characterization of the ligand-RAGE-interaction. These studies will provide a rationale for the development of new therapeutic approaches for accelerated atherosclerosis in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15340736     DOI: 10.1007/s00059-004-2611-3

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  6 in total

Review 1.  [Urosepsis and treatment].

Authors:  F M E Wagenlehner; C Lichtenstern; M A Weigand; W Weidner
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

2.  Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population.

Authors:  Robert P van Waateringe; Bernardina T Fokkens; Sandra N Slagter; Melanie M van der Klauw; Jana V van Vliet-Ostaptchouk; Reindert Graaff; Andrew D Paterson; Andries J Smit; Helen L Lutgers; Bruce H R Wolffenbuttel
Journal:  Diabetologia       Date:  2018-11-21       Impact factor: 10.122

3.  Skin autofluorescence predicts new cardiovascular disease and mortality in people with type 2 diabetes.

Authors:  Henderikus E Boersma; Robert P van Waateringe; Melanie M van der Klauw; Reindert Graaff; Andrew D Paterson; Andries J Smit; Bruce H R Wolffenbuttel
Journal:  BMC Endocr Disord       Date:  2021-01-12       Impact factor: 2.763

Review 4.  Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.

Authors:  Zhenghong Liu; Xiaoxuan Ma; Iqra Ilyas; Xueying Zheng; Sihui Luo; Peter J Little; Danielle Kamato; Amirhossein Sahebkar; Weiming Wu; Jianping Weng; Suowen Xu
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

Review 5.  Diabetic Pneumopathy-A New Diabetes-Associated Complication: Mechanisms, Consequences and Treatment Considerations.

Authors:  Stefan Kopf; Varun Kumar; Zoltan Kender; Zhe Han; Thomas Fleming; Stephan Herzig; Peter P Nawroth
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-25       Impact factor: 5.555

Review 6.  Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.

Authors:  Lei Xiao; Xin Nie; Yanyan Cheng; Nanping Wang
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-17       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.